Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Illness perception (assessed by BIPQ) following omalizumab treatment at each time point (longitudinal population)

From: Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Component

Baseline

Change at 6 months from baseline

P-value

Change at 12 months from baseline

P-value

Consequences

7.3 ± 1.9

−2.0 ± 2.4

< 0.0001

−2.2 ± 2.7

< 0.0001

Timeline

8.1 ± 2.4

−1.0 ± 2.5

< 0.0001

−0.3 ± 2.4

0.1938

Personal control

5.9 ± 2.0

0.7 ± 2.3

0.0005

0.9 ± 2.5

0.0003

Treatment control

7.2 ± 2.3

0.9 ± 2.6

0.0001

1.1 ± 2.5

< 0.0001

Identity

7.6 ± 1.7

−2.2 ± 2.5

< 0.0001

−2.0 ± 2.6

< 0.0001

Concern

7.4 ± 2.3

−1.6 ± 3.0

< 0.0001

− 1.7 ± 3.0

< 0.0001

Emotions

7.0 ± 2.6

−1.2 ± 2.8

< 0.0001

−1.1 ± 3.0

< 0.0001

Illness comprehensibility

7.1 ± 2.3

0.4 ± 2.3

0.0690

0.7 ± 2.4

0.0076

  1. Data presented as mean ± SD
  2. P < 0.05 is considered as statistically significant. P-value was calculated using Wilcoxon test
  3. BIPQ Brief Illness Perception Questionnaire
Back to article page

World Allergy Organization Journal

ISSN: 1939-4551

Contact us